|
Atherosclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
It is of great interest to understand the stereochemical selectivity of 20(R/S)-Rg3 and explore whether differential PPARγ activation by Rg3 stereoisomers, if it exists, could lead to differential physiological outcome and therapeutic effects in diabetic atherosclerosis.
|
29566305 |
2018 |
|
Atherosclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
We tested whether lobeglitazone, a new PPARγ agonist, might protect against atherosclerosis.
|
26363808 |
2015 |
|
Atherosclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Finally, as more PPARgamma targeted pathways are revealed such as bone homeostasis, atherosclerosis and longevity, it is most certain that the PPARgamma thrifty gene hypothesis will evolve to incorporate these.
|
15667578 |
2005 |
|
Atherosclerosis
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Pharmacological activation of PPARgamma expressed in VSMCs inhibits their proliferation and migration, potentially limiting restenosis and atherosclerosis.
|
10725292 |
2000 |
|
Atherosclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
According to the results of a preliminary study, it was hypothesized that the effects of adiponectin (APN) on the improvement of atherosclerosis may be associated with adipocyte differentiation and peroxisome proliferator‑activated receptor γ (PPARγ).
|
29115433 |
2018 |
|
Atherosclerosis
|
0.500 |
Biomarker
|
disease |
LHGDN |
In conclusion, stimulation of CYP27A1 by PPARgamma may represent a key previously unrecognized mechanism by which PPARgamma protects against atherosclerosis.
|
15533057 |
2005 |
|
Atherosclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
The wide spectrum of PPAR-γ activation effects may be beneficial for treatment of various cardiovascular conditions as atherosclerosis, hypertension and aortic aneurysm, including surgical interventions.
|
27855608 |
2017 |
|
Atherosclerosis
|
0.500 |
PosttranslationalModification
|
disease |
LHGDN |
Homocysteine-mediated PPARalpha,gamma DNA methylation and its potential pathogenic mechanism in monocytes.
|
18004978 |
2008 |
|
Atherosclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
We report here that the PPARgamma-specific agonists rosiglitazone and GW7845 strongly inhibited the development of atherosclerosis in LDL receptor-deficient male mice, despite increased expression of the CD36 scavenger receptor in the arterial wall.
|
10953027 |
2000 |
|
Atherosclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
The ongoing clinical use of fibrates, which activate PPARalpha, and thiazolidinediones, which activate PPARgamma, establishes these receptors as viable drug targets, whereas considerable in vitro animal model and human surrogate marker studies suggest that PPAR activation may limit inflammation and atherosclerosis.
|
17261671 |
2007 |
|
Atherosclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
These results suggested that AGP plays a significant role in the initiation/progression of diabetes-related atherosclerosis through PPARγ activation.
|
29355589 |
2018 |
|
Atherosclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Macrophage lipid metabolism is transcriptionally regulated by peroxisome proliferator-activated receptor gamma (PPARγ), and its target gene fatty acid binding protein 4 (FABP4) accelerates the progression of atherosclerosis in mouse models.
|
25897794 |
2015 |
|
Atherosclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Activation of macrophage ABCA1/G1 expression and cholesterol efflux is believed one of the mechanisms by which PPARγ inhibits atherosclerosis.
|
27890613 |
2017 |
|
Atherosclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
BACKGROUND Peroxisome proliferator-activated receptor gamma (PPARgamma) is involved mainly in adipocyte differentiation and has been suggested to play an important role in the pathogenesis of insulin resistance (IR) and atherosclerosis.
|
18362424 |
2008 |
|
Atherosclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
And the underlying mechanism of OA on atherosclerosis may involve in lipid metabolism genes: PPARγ, AdipoR1, and AdipoR2.
|
28338883 |
2017 |
|
Atherosclerosis
|
0.500 |
Therapeutic
|
disease |
CTD_human |
[Rosiglitazone enhances the anti-atherosclerotic effects of peroxisome proliferator-activated receptor gamma1 gene transfer in apolipoprotein-knock out mice].
|
18269830 |
2007 |
|
Atherosclerosis
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Recent studies showed that PPARgamma is also expressed in monocytes/macrophages and is suggested to be involved in atherosclerosis.
|
11500181 |
2001 |
|
Atherosclerosis
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
<b>Results:</b> Our results indicated that the protein levels of HMGB1, TLR4, and pro-inflammatory cytokines including IL-1β, TNF-α were elevated with the development of atherosclerosis in CUMS mice, while the expressions of PPARγ, LXRα, and ABCA1 declined.
|
30881312 |
2019 |
|
Atherosclerosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Peroxisome proliferator-activated receptor gamma-2 gene (PPARγ2) rs1801282 (Pro12Ala) polymorphism has been associated with lower risk of metabolic disturbance and atherosclerosis.
|
25159899 |
2014 |
|
Atherosclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
This issue is important because thiazolidinediones, which are ligands for PPARgamma, have recently been approved for the treatment of type 2 diabetes, a state of accelerated atherosclerosis.
|
11231915 |
2001 |
|
Atherosclerosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The interaction result for S(I) was replicated by the Insulin Resistance Atherosclerosis Family Study (P = 0.018) in their San Antonio sample (n = 484) where subjects with at least one PPARG2 Ala allele and homozygous for the HNF4A rs2144908 A allele had a 29% higher S(I) compared with individuals with at least one G allele.
|
18162503 |
2008 |
|
Atherosclerosis
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Notably, additional Tg(PPAR-γ) or pharmacological activation of PPAR-γ effectively prevented Tg(DNMT1)-induced proinflammatory cytokine production in macrophages and AS development in the mouse model.
|
27530451 |
2016 |
|
Atherosclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
In conclusion, TSPG could inhibit the maturation of DCs induced by oxidized-LDL which suggests beneficial effects on atherosclerosis and this effect was partly dependent on the PPARgamma pathway at least.
|
20362279 |
2010 |
|
Atherosclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Our findings show that macrophage NCOR1 blocks the pro-atherogenic functions of PPARγ in atherosclerosis and suggest that stabilizing the NCOR1-PPARγ binding could be a promising strategy to block the pro-atherogenic functions of plaque macrophages and lesion progression in atherosclerotic patients.
|
31529020 |
2020 |
|
Atherosclerosis
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Peroxisome proliferator-activated receptor gamma (PPARG) is a transcription factor involved in atherosclerosis and related diseases.
|
27264718 |
2016 |